Vivos Inc

What Vivos Inc does

Vivos Inc is a clinical-stage medical device company developing Precision Radionuclide Therapy™ (PRnT™), a Yttrium-90 based injectable hydrogel platform that delivers highly localized beta radiation directly into solid tumors. The core technology uses Y-90 phosphate particles smaller than 2.0 µm suspended in a PLGA-g-PEG co-polymer hydrogel that gels in place within 15-30 seconds after injection, sequestering radioactive particles and inhibiting migration. The Y-90 isotope has a maximum beta energy of 2.3 MeV, a maximum path length of 11 mm, and a 2.67-day physical half-life, producing an average path length of 4.7 mm that localizes dose to tumor tissue while sparing healthy surrounding tissue.

The company operates two divisions. IsoPet® provides PRnT™ for solid tumors in companion animals (cats, dogs, and horses) through 8 certified regional veterinary clinics across the United States, including University of Missouri, Johns Hopkins Medicine, and University of Wisconsin, and has been operating since 2018. RadioGel® is the human cancer treatment division targeting solid tumors, with initial focus on papillary thyroid cancer through a Mayo Clinic collaboration; the product is not yet FDA-approved and the company submitted an Investigational Device Exemption application on June 28, 2024, following FDA Breakthrough Device Designation. International expansion is being pursued through India human trials pending DCGI regulatory approval.

Vivos Inc is incorporated in Washington State, headquartered in Kennewick, WA, and publicly traded on the OTCQB market under ticker RDGL, having achieved Section 12(g) Exchange Act registration on March 22, 2024. The intellectual property estate comprises nearly 30 patents, with CEO Dr. Michael Korenko personally holding 28 patents. Revenue mechanics on the veterinary side rely on treatment service fees at certified partner clinics; the human side is pre-commercial with no pricing or revenue disclosed pending FDA approval.

Name

Vivos Inc

Legal name

Vivos Inc.

Website

https://radiogel.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Vivos Inc is a clinical-stage medical device company developing Yttrium-90 based Precision Radionuclide Therapy™ for solid tumors. It operates IsoPet® (veterinary oncology at 8 US clinics since 2018) and RadioGel® (pre-commercial human cancer treatment, pending FDA IDE approval).

Ownership category

akta.pro rank

Product category

Radiation Oncology Medical Devices

NAICS

Irradiation Apparatus Manufacturing (334517), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Companion Animal Therapeutics (Rx) (HLAMAEAA), Oncology & Specialty Therapeutics (HLAMAEAJ)

Keywords

• Precision radionuclide therapy
• Brachytherapy devices
• Veterinary oncology
• Radiopharmaceutical hydrogel
• Radiation oncology devices

Headquarters

HQ city

Kennewick

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. IsoPet® Veterinary Treatment Services: Revenue generated from providing cancer treatment services for animals (cats, dogs, horses) at 8 certified regional clinics across the United States. Treatments include solid tumor therapy using Yttrium-90 based Precision Radionuclide Therapy™.
2. RadioGel® Human Treatment (Future): Pre-commercial stage. RadioGel® division is developing human cancer treatment. Currently not approved for human use. Company is pursuing FDA IDE submission to begin clinical trials. Human trials are taking place in India.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Vivos Inc develops and supplies Yttrium-90 based injectable hydrogel medical devices based on its patented Precision Radionuclide Therapy™ (PRnT™) platform for the treatment of solid tumors. The company operates two divisions: IsoPet®, which delivers PRnT™ cancer treatments for companion animals (cats, dogs, horses) through 8 certified regional veterinary clinics across the United States, and RadioGel®, a pre-commercial human oncology division pursuing FDA IDE approval with a Breakthrough Device Designation and parallel clinical trials in India. The hydrogel device contains Y-90 phosphate particles (<2.0 µm) in a PLGA-g-PEG polymer that gels in 15-30 seconds after injection, confining localized beta radiation to the tumor.

Product overview

Vivos Inc. is a clinical-stage medical device company developing precision radionuclide therapy products for cancer treatment. The company operates two divisions: RadioGel® for human cancer treatment and IsoPet® for veterinary oncology. The core technology, Precision Radionuclide Therapy™ (PRnT™), utilizes a Yttrium-90 based injectable hydrogel device that delivers localized beta radiation directly into solid tumors. The product portfolio includes trademarked variants (Alpha-Gel™, Beta-Gel™, Gamma-Gel™) alongside the primary offerings. RadioGel® is undergoing FDA regulatory review for human use, while IsoPet® is currently available through 8 certified animal clinics across the United States.

Differentiator

Problem solved

Functional benefit

Brands

• RadioGel®: Precision Radionuclide Therapy™ division for human cancer treatment using Yttrium-90 based injectable device (not currently approved for human use).
• IsoPet®
• Alpha-Gel™
• Beta-Gel™
• Gamma-Gel™

Products and services

• IsoPet® A Yttrium-90 based Precision Radionuclide Therapy™ (PRnT™) device for treating solid tumors in companion animals (cats, dogs, and horses). Available commercially through 8 certified regional veterinary clinics across the United States, including University of Missouri, Johns Hopkins Medicine, and University of Wisconsin.
• RadioGel® A Yttrium-90 based Precision Radionuclide Therapy™ (PRnT™) device for treating solid tumors in humans via direct injection into cancerous tissue. Currently not FDA-approved for human use; pursuing FDA IDE approval and Breakthrough Device Designation with initial indication in papillary thyroid cancer lymph node metastases through Mayo Clinic collaboration.
• Precision Radionuclide Therapy™ (PRnT™) Patented core treatment methodology and underlying technology platform used by both IsoPet® and RadioGel®, employing Yttrium-90 phosphate particles (<2.0 µm) suspended in a PLGA-g-PEG co-polymer hydrogel that delivers localized beta radiation directly into tumors.

Quantifiable outcome

• High therapeutic index with negligible non-target radiation
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• Mayo CliniccoreStrategic or Co-development PartnerStrategic collaboration for initial indication of RadioGel® for delivering therapeutic radiation to solid metastatic tumors in lymph nodes associated with papillary thyroid cancer. The company is working closely with Mayo Clinic for the initial indication, accessible by percutaneous direct needle injection, in patients who are not surgical candidates or have declined surgery, had non-radioiodine avid disease and had limited burden regional nodal disease.
• University of MissouricoreChannel Partner/ Reseller/ DistributorKey regional clinic certified to offer IsoPet® treatment for animal cancer in horses, cats, and dogs.
• Johns Hopkins MedicinecoreChannel Partner/ Reseller/ DistributorKey regional clinic certified to offer IsoPet® treatment for animal cancer in horses, cats, and dogs.
• University of WisconsincoreChannel Partner/ Reseller/ DistributorMost recently certified regional clinic for equine cancer treatment with IsoPet® Precision Radionuclide Therapy™.
• DCGI (Drugs Controller General of India)coreOthersIndian regulatory authority reviewing the company's application for expansion of human therapy trials with RadioGel® Precision Radionuclide Therapy™ in India. Approval has experienced delays beyond original target timeframe of end of March 2026.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Novartis: Maker of Pluvicto (Lu-177 PSMA-617) and Lutathera (Lu-177 dotatate), both approved therapeutic radioligands for solid tumors. While Novartis uses a different isotope (Lu-177) and systemic ligand delivery versus Vivos's direct-injection Y-90 hydrogel, both companies target the same therapeutic radiopharmaceutical opportunity and overlapping oncology indications.
• Eli Lilly: Acquired POINT Biopharma in 2023 to enter radioligand therapy with a Lu-177 PSMA program. While Lilly is far larger, its POINT subsidiary is a directly comparable therapeutic radiopharmaceutical peer targeting similar oncology indications.

Emerging players

• PetCure Oncology: Veterinary radiation oncology services provider offering advanced cancer treatment for companion animals. Direct comparable for Vivos's IsoPet® division in veterinary oncology delivery model and target customer (pet owners seeking advanced cancer treatment).
• Viewpoint Molecular Targeting: Clinical-stage radiopharmaceutical company developing alpha- and beta-emitting therapeutics for cancer. Comparable small-cap, clinical-stage profile and similar therapeutic radionuclide approach to Vivos's Y-90 platform.
• IsoRay Medical: Brachytherapy medical-device company that developed the Cs-131 seed (the FDA-cleared product that Vivos's CTO David Swanberg previously led). Closely comparable technology category (internal radiation therapy), at a similar small-cap clinical stage, with shared leadership lineage.

Direct peers

• Curium Pharma: Global radiopharmaceutical company with a portfolio spanning diagnostic and therapeutic nuclear medicine products. Direct overlap with Vivos in nuclear medicine infrastructure and radiopharmaceutical product development, including oncology therapeutics.
• ITM Isotope Technologies Munich: Privately held developer of therapeutic radiopharmaceuticals (including Lu-177 and other medical radioisotopes) targeting solid tumors. Comparable size, therapeutic focus, and clinical-stage profile to Vivos in the radiopharmaceutical oncology space.
• Lantheus Holdings: Radiopharmaceutical company with an approved diagnostic imaging franchise and growing therapeutic pipeline, including partnerships in Lu-177-based radioligand therapy. Comparable in radiopharmaceutical category and oncology focus, with overlapping solid-tumor indications.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with approved PSMA imaging agent (Illuccix) and a pipeline of Lu-177 and alpha-emitter therapeutic radiopharmaceuticals targeting solid tumors. Highly comparable in therapeutic approach and target indications, but at a later commercialization stage.

Others

• Bayer: Through its pharmaceutical division, Bayer markets Xofigo (radium-223 dichloride), an approved therapeutic radiopharmaceutical for castration-resistant prostate cancer bone metastases. Direct overlap with Vivos's therapeutic-radiopharmaceutical category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/isotopeworld
• Facebookfacebook.com/Advanced-Medical-Isotope-Corporati
• LinkedInlinkedin.com/company/advanced-medical-isotope-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivos Inc